Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Onyx Pharmaceuticals ( ONXX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.6%. By the end of trading, Onyx Pharmaceuticals fell $1.18 (-1.3%) to $88.80 on light volume. Throughout the day, 733,942 shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 1,144,100 shares. The stock ranged in price between $87.16-$90.36 after having opened the day at $90.23 as compared to the previous trading day's close of $89.98. Other companies within the Drugs industry that declined today were: Biota Pharmaceuticals ( BOTA), down 68.0%, MannKind Corporation ( MNKD), down 12.4%, Opexa Therapeutics ( OPXA), down 11.3% and Oramed Pharmaceuticals ( ORMP), down 7.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $6.6 billion and is part of the health care sector. Shares are up 19.3% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow.

On the positive front, Cytokinetics ( CYTK), down 29.4%, Prothena Corporation ( PRTA), down 16.0%, Infinity Pharmaceuticals ( INFI), down 13.3% and TG Therapeutics ( TGTX), down 11.1% , were all gainers within the drugs industry with Biogen Idec ( BIIB) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.